Badros A - Search Results

1

The Role of Immunotherapy in Multiple Myeloma.

Kocoglu M, Badros A. Kocoglu M, et al. Among authors: badros a. Pharmaceuticals (Basel). 2016 Jan 14;9(1):3. doi: 10.3390/ph9010003. Pharmaceuticals (Basel). 2016. PMID: 26784207 Free PMC article. Review.

2

The role of maintenance therapy in the treatment of multiple myeloma.

Badros AZ. Badros AZ. J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S21-7. doi: 10.6004/jnccn.2010.0113. J Natl Compr Canc Netw. 2010. PMID: 20141671

3

Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials.

Bazzi M, Badros A. Bazzi M, et al. Among authors: badros a. Cancer Biol Ther. 2010 Nov 1;10(9):830-8. doi: 10.4161/cbt.10.9.13622. Epub 2010 Nov 1. Cancer Biol Ther. 2010. PMID: 21045554 Review.

4

Role of carfilzomib in the treatment of multiple myeloma.

Khan RZ, Badros A. Khan RZ, et al. Among authors: badros a. Expert Rev Hematol. 2012 Aug;5(4):361-72. doi: 10.1586/ehm.12.26. Expert Rev Hematol. 2012. PMID: 22992230

5

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, Kocoglu M, Lederer E, Philip S, Milliron T, Dell C, Goloubeva O, Singh Z. Badros A, et al. Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1. Blood. 2017. PMID: 28461396 Free article. Clinical Trial.

6

Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.

Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, Ruehle K, Kocoglu MH, Badros A, Hardy N, Yared J, Rapoport AP, Fontaine M, Emadi A, El Chaer F, Dahiya S. Bathini S, et al. Among authors: badros a. Am J Hematol. 2019 Aug;94(8):E216-E219. doi: 10.1002/ajh.25515. Epub 2019 Jun 7. Am J Hematol. 2019. PMID: 31120638 Free article. No abstract available.

7

Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.

Duong VH, Holtzman NG, Koka R, Singh ZN, Zou Y, Emadi A, Rapoport AP, Kocoglu MH, Baer MR, Badros AZ. Duong VH, et al. Among authors: badros az. Leuk Lymphoma. 2019 Dec;60(14):3577-3580. doi: 10.1080/10428194.2019.1633639. Epub 2019 Jul 8. Leuk Lymphoma. 2019. PMID: 31282234 Clinical Trial. No abstract available.

8

Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.

Bukhari A, El Chaer F, Koka R, Singh Z, Hutnick E, Ruehle K, Lee ST, Kocoglu MH, Shanholtz C, Badros A, Hardy N, Yared J, Rapoport AP, Dahiya S. Bukhari A, et al. Among authors: badros a. Am J Hematol. 2019 Oct;94(10):E273-E275. doi: 10.1002/ajh.25591. Epub 2019 Aug 13. Am J Hematol. 2019. PMID: 31342556 Free article. No abstract available.

9

Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond.

Kocoglu MH, Badros AZ. Kocoglu MH, et al. Expert Rev Hematol. 2020 Jun;13(6):669-686. doi: 10.1080/17474086.2020.1756258. Epub 2020 Apr 27. Expert Rev Hematol. 2020. PMID: 32290719 Review.

10

Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.

Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, Lutfi F, Siglin J, Hutnick E, Gahres N, Ruehle K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S. Holtzman NG, et al. Among authors: badros az. Neuro Oncol. 2021 Jan 30;23(1):112-121. doi: 10.1093/neuonc/noaa183. Neuro Oncol. 2021. PMID: 32750704 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

156 results

Search Page